Legend Biotech (NASDAQ:LEGN) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.23) by 69.57 percent. This is a 69.57 percent increase over losses of $(0.23) per share from the same period last year. The company reported quarterly sales of $195.05 million which beat the analyst consensus estimate of $193.62 million by 0.74 percent. This is a 107.52 percent increase over sales of $93.99 million the same period last year.